Adult Memory T Cell Responses to the Respiratory Syncytial Virus Fusion Protein During a Single RSV Season (2018–2019)

Respiratory Syncytial Virus (RSV) is ubiquitous and re-infection with both subtypes (RSV/A and RSV/B) is common. The fusion (F) protein of RSV is antigenically conserved, induces neutralizing antibodies, and is a primary target of vaccine development. Insight into the breadth and durability of RSV-specific adaptive immune response, particularly to the F protein, may shed light on susceptibility to re-infection. We prospectively enrolled healthy adult subjects (n = 19) and collected serum and peripheral blood mononuclear cells (PBMCs) during the 2018–2019 RSV season. Previously, we described their RSV-specific antibody responses and identified three distinct antibody kinetic profiles associated with infection status: uninfected (n = 12), acutely infected (n = 4), and recently infected (n = 3). In this study, we measured the longevity of RSV-specific memory T cell responses to the F protein following natural RSV infection. We stimulated PBMCs with overlapping 15-mer peptide libraries spanning the F protein derived from either RSV/A or RSV/B and found that memory T cell responses mimic the antibody responses for all three groups. The uninfected group had stable, robust memory T cell responses and polyfunctionality. The acutely infected group had reduced polyfunctionality of memory T cell response at enrollment compared to the uninfected group, but these returned to comparable levels by end-of-season. The recently infected group, who were unable to maintain high levels of RSV-specific antibody following infection, similarly had decreased memory T cell responses and polyfunctionality during the RSV season. We observed subtype-specific differences in memory T cell responses and polyfunctionality, with RSV/A stimulating stronger memory T cell responses with higher polyfunctionality even though RSV/B was the dominant subtype in circulation. A subset of individuals demonstrated an overall deficiency in the generation of a durable RSV-specific adaptive immune response. Because memory T cell polyfunctionality may be associated with protection against re-infection, this latter group would likely be at greater risk of re-infection. Overall, these results expand our understanding of the longevity of the adaptive immune response to the RSV fusion protein and should be considered in future vaccine development efforts.

[1]  M. Pierer,et al.  Expansion of CD4+CD8+ Double-positive T cells in Rheumatoid Arthritis Patients is Associated with Erosive Disease. , 2021, Rheumatology.

[2]  P. Piedra,et al.  A prospective surveillance study on the kinetics of the humoral immune response to the respiratory syncytial virus fusion protein in adults in Houston, Texas. , 2021, Vaccine.

[3]  P. Sopp,et al.  Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19 , 2020, Nature Immunology.

[4]  C. Burger,et al.  The Role of PD-1 in Acute and Chronic Infection , 2020, Frontiers in Immunology.

[5]  R. Mikolajczyk,et al.  Global Disease Burden Estimates of Respiratory Syncytial Virus-Associated Acute Respiratory Infection in Older Adults in 2015: A Systematic Review and Meta-Analysis. , 2019, The Journal of infectious diseases.

[6]  Mark A. Miller,et al.  The Etiological Role of Common Respiratory Viruses in Acute Respiratory Infections in Older Adults: A Systematic Review and Meta-analysis , 2019, The Journal of infectious diseases.

[7]  Leland McInnes,et al.  UMAP: Uniform Manifold Approximation and Projection , 2018, J. Open Source Softw..

[8]  G. Freeman,et al.  Role of PD-1 during effector CD8 T cell differentiation , 2018, Proceedings of the National Academy of Sciences.

[9]  Leland McInnes,et al.  UMAP: Uniform Manifold Approximation and Projection for Dimension Reduction , 2018, ArXiv.

[10]  D. Meyerholz,et al.  Memory CD8 T cells mediate severe immunopathology following respiratory syncytial virus infection , 2018, PLoS pathogens.

[11]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[12]  M. Lucero,et al.  Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study , 2017, The Lancet.

[13]  C. Shaw,et al.  Sequence variability of the respiratory syncytial virus (RSV) fusion gene among contemporary and historical genotypes of RSV/A and RSV/B , 2017, PloS one.

[14]  J. McLellan,et al.  Structural, antigenic and immunogenic features of respiratory syncytial virus glycoproteins relevant for vaccine development. , 2017, Vaccine.

[15]  M. Schmitt,et al.  Standardization of cryopreserved peripheral blood mononuclear cells through a resting process for clinical immunomonitoring—Development of an algorithm , 2016, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[16]  Bjoern Peters,et al.  Epitope specific T‐cell responses against influenza A in a healthy population , 2016, Immunology.

[17]  A. Falsey,et al.  Respiratory Syncytial Virus Infection in Older Adults: An Under-Recognized Problem , 2015, Drugs & Aging.

[18]  Deborah Hix,et al.  The immune epitope database (IEDB) 3.0 , 2014, Nucleic Acids Res..

[19]  T. Matano,et al.  Vaccine-Induced CD107a+ CD4+ T Cells Are Resistant to Depletion following AIDS Virus Infection , 2014, Journal of Virology.

[20]  M. Shlomchik,et al.  A Temporal Switch in the Germinal Center Determines Differential Output of Memory B and Plasma Cells. , 2014, Immunity.

[21]  Philip E. Bourne,et al.  Immune epitope database analysis resource , 2012, Nucleic Acids Res..

[22]  G. Ferrari,et al.  CD4+CD8+ T Cells Represent a Significant Portion of the Anti-HIV T Cell Response to Acute HIV Infection , 2012, The Journal of Immunology.

[23]  E. Walsh,et al.  Respiratory syncytial virus infection in adult populations. , 2012, Infectious disorders drug targets.

[24]  P. Piedra,et al.  Role of Neutralizing Antibodies in Adults With Community-Acquired Pneumonia by Respiratory Syncytial Virus , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[25]  Mario Roederer,et al.  SPICE: Exploration and analysis of post‐cytometric complex multivariate datasets , 2011, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[26]  Morten Nielsen,et al.  Peptide binding predictions for HLA DR, DP and DQ molecules , 2010, BMC Bioinformatics.

[27]  S. Madhi,et al.  Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis , 2010, The Lancet.

[28]  James McCluskey,et al.  The peptide length specificity of some HLA class I alleles is very broad and includes peptides of up to 25 amino acids in length. , 2009, Molecular immunology.

[29]  C. Terrosi,et al.  Humoral immunity to respiratory syncytial virus in young and elderly adults , 2009, Epidemiology and Infection.

[30]  Peter Aaby,et al.  Respiratory syncytial virus neutralizing antibodies in cord blood, respiratory syncytial virus hospitalization, and recurrent wheeze. , 2009, The Journal of allergy and clinical immunology.

[31]  J. Reed,et al.  Respiratory syncytial virus and influenza virus infections: observations from tissues of fatal infant cases. , 2008, The Pediatric infectious disease journal.

[32]  Qing Zhang,et al.  Immune epitope database analysis resource (IEDB-AR) , 2008, Nucleic Acids Res..

[33]  M. Roederer,et al.  T-cell quality in memory and protection: implications for vaccine design , 2008, Nature Reviews Immunology.

[34]  Mario Roederer,et al.  Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major , 2007, Nature Medicine.

[35]  Mario Roederer,et al.  Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8+ T cell responses , 2007, The Journal of experimental medicine.

[36]  H. Robinson,et al.  Multiple-Cytokine-Producing Antiviral CD4 T Cells Are Functionally Superior to Single-Cytokine-Producing Cells , 2007, Journal of Virology.

[37]  R. Koup,et al.  Acquisition of direct antiviral effector functions by CMV-specific CD4+ T lymphocytes with cellular maturation , 2006, The Journal of experimental medicine.

[38]  Alison Johnson,et al.  Changes in Paracrine Interleukin-2 Requirement, CCR7 Expression, Frequency, and Cytokine Secretion of Human Immunodeficiency Virus-Specific CD4+ T Cells Are a Consequence of Antigen Load , 2006, Journal of Virology.

[39]  M. Betts,et al.  Polyfunctional analysis of human t cell responses: importance in vaccine immunogenicity and natural infection , 2006, Springer Seminars in Immunopathology.

[40]  Mario Roederer,et al.  HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. , 2006, Blood.

[41]  R. Koup,et al.  HIV Gag protein conjugated to a Toll-like receptor 7/8 agonist improves the magnitude and quality of Th1 and CD8+ T cell responses in nonhuman primates. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[42]  E. Walsh,et al.  Experimental infection of humans with A2 respiratory syncytial virus. , 2004, Antiviral research.

[43]  L. Chiriboga,et al.  Peripheral CD4(+)CD8(+) T cells are differentiated effector memory cells with antiviral functions. , 2004, Blood.

[44]  W. P. Glezen,et al.  Correlates of immunity to respiratory syncytial virus (RSV) associated-hospitalization: establishment of minimum protective threshold levels of serum neutralizing antibodies. , 2003, Vaccine.

[45]  V. Maino,et al.  CD4+CD8dim T lymphocytes exhibit enhanced cytokine expression, proliferation and cytotoxic activity in response to HCMV and HIV‐1 antigens , 2001, European journal of immunology.

[46]  E. Walsh,et al.  Relationship of serum antibody to risk of respiratory syncytial virus infection in elderly adults. , 1998, The Journal of infectious diseases.

[47]  A. Mccarthy.  Development , 1996, Current Opinion in Neurobiology.

[48]  William S. Lane,et al.  Predominant naturally processed peptides bound to HLA-DR1 are derived from MHC-related molecules and are heterogeneous in size , 1992, Nature.

[49]  B. Graham,et al.  Role of T lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice. , 1991, The Journal of clinical investigation.

[50]  E. Walsh,et al.  Immunity to and frequency of reinfection with respiratory syncytial virus. , 1991, The Journal of infectious diseases.

[51]  H. Ochs,et al.  The half-lives of IgG subclasses and specific antibodies in patients with primary immunodeficiency who are receiving intravenously administered immunoglobulin. , 1988, The Journal of laboratory and clinical medicine.

[52]  B A Askonas,et al.  Cytotoxic T cells clear virus but augment lung pathology in mice infected with respiratory syncytial virus , 1988, The Journal of experimental medicine.

[53]  Klaus Rajewsky,et al.  The half‐lives of serum immunoglobulins in adult mice , 1988, European journal of immunology.

[54]  A. Frank,et al.  Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level. , 1981, The Journal of pediatrics.

[55]  P. Piedra,et al.  Respiratory Syncytial Virus (RSV): Neutralizing Antibody, a Correlate of Immune Protection. , 2016, Methods in molecular biology.

[56]  P. Hiatt,et al.  Purified fusion protein vaccine protects against lower respiratory tract illness during respiratory syncytial virus season in children with cystic fibrosis. , 1996, The Pediatric infectious disease journal.